Back to Search Start Over

Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1

Authors :
Jonathan M. Payne
Stephen J. C. Hearps
Karin S. Walsh
Iris Paltin
Belinda Barton
Nicole J. Ullrich
Kristina M. Haebich
David Coghill
Gerard A. Gioia
Alan Cantor
Gary Cutter
James H. Tonsgard
David Viskochil
Celiane Rey‐Casserly
Elizabeth K. Schorry
Joseph D. Ackerson
Laura Klesse
Michael J. Fisher
David H. Gutmann
Tena Rosser
Roger J. Packer
Bruce Korf
Maria T. Acosta
Kathryn N. North
the NF Clinical Trials Consortium
Source :
Annals of Clinical and Translational Neurology, Vol 6, Iss 12, Pp 2555-2565 (2019)
Publication Year :
2019
Publisher :
Wiley, 2019.

Abstract

Abstract Objective Rapid developments in understanding the molecular mechanisms underlying cognitive deficits in neurodevelopmental disorders have increased expectations for targeted, mechanism‐based treatments. However, translation from preclinical models to human clinical trials has proven challenging. Poor reproducibility of cognitive endpoints may provide one explanation for this finding. We examined the suitability of cognitive outcomes for clinical trials in children with neurofibromatosis type 1 (NF1) by examining test‐retest reliability of the measures and the application of data reduction techniques to improve reproducibility. Methods Data were analyzed from the STARS clinical trial (n = 146), a multi‐center double‐blind placebo‐controlled phase II trial of lovastatin, conducted by the NF Clinical Trials Consortium. Intra‐class correlation coefficients were generated between pre‐ and post‐performances (16‐week interval) on neuropsychological endpoints in the placebo group to determine test‐retest reliabilities. Confirmatory factor analysis was used to reduce data into cognitive domains and account for measurement error. Results Test‐retest reliabilities were highly variable, with most endpoints demonstrating unacceptably low reproducibility. Data reduction confirmed four distinct neuropsychological domains: executive functioning/attention, visuospatial ability, memory, and behavior. Test‐retest reliabilities of latent factors improved to acceptable levels for clinical trials. Applicability and utility of our model was demonstrated by homogeneous effect sizes in the reanalyzed efficacy data. Interpretation These data demonstrate that single observed endpoints are not appropriate to determine efficacy, partly accounting for the poor test‐retest reliability of cognitive outcomes in clinical trials in neurodevelopmental disorders. Recommendations to improve reproducibility are outlined to guide future trial design.

Details

Language :
English
ISSN :
23289503
Volume :
6
Issue :
12
Database :
Directory of Open Access Journals
Journal :
Annals of Clinical and Translational Neurology
Publication Type :
Academic Journal
Accession number :
edsdoj.213a2426d5c645e994f7b2496477dbb2
Document Type :
article
Full Text :
https://doi.org/10.1002/acn3.50952